Moderna has dropped a patent application for a key part of its vaccine amid controversy with the US National Institutes of Health (NIH) over which scientists should be credited as its inventors, postponing a possible legal dispute between the company. and the government, Forbes reported.
In 2020, Moderna applied for a patent for a genetic sequence used in its vaccine to activate the coronavirus immune response.
In this Moderna stated that the NIHs were “collaborators” in the development of the vaccine, while only the scientists of the company were mentioned as inventors.
The NIH asked Moderna to add the names of three government researchers to the inventors, sparking a public controversy over who developed the genetic sequence.
Listing these scientists as inventors could allow the NIH to collect billions of dollars in sales of the vaccine and grant the patent to vaccine manufacturers in countries where access to vaccines is low.
Moderna, after losing its payment deadline on November 29, dropped the current application and filed a new one that could allow the patent to be issued at a later date, the company said.
The delay will allow more time for discussions between Moderna and the NIH, according to Moderna.
.
Source: Forbes

Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.